
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3138468/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ustekinumab Therapeutic Drug Monitoring—Impact on Clinical Practice: A Multicenter Cross-Sectional Observational Trial. Digestive Diseases and Sciences, 2022, 67, 3148-3157.	2.3	4
2	Canadian Consensus Statements on the Transition of Adolescents and Young Adults with Inflammatory Bowel Disease from Pediatric to Adult Care: A Collaborative Initiative Between the Canadian IBD Transition Network and Crohn's and Colitis Canada. Journal of the Canadian Association of Gastroenterology, 2022, 5, 105-115.	0.3	8
3	Defining Transition Success for Young Adults with Inflammatory Bowel Disease According to Patients, Parents and Health Care Providers. Journal of the Canadian Association of Gastroenterology, 2022, 5, 192-198.	0.3	2
4	Tenofovir disoproxil fumarate therapy to prevent hepatitis B virus vertical transmission—A review of maternal and infant outcomes. Liver International, 2022, 42, 1712-1730.	3.9	7
5	Association between chronic conditions and urinary incontinence in females: a cross-sectional study using national survey data. CMAJ Open, 2022, 10, E296-E303.	2.4	5
6	Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response. Journal of the Canadian Association of Gastroenterology, 2022, 5, 208-213.	0.3	6
7	Observational data from the adalimumab postâ€marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis. United European Gastroenterology Journal, 2022, 10, 485-495.	3.8	3
8	Frequency of Opioid Prescription at Emergency Department Discharge in Patients with Inflammatory Bowel Disease: A Nationwide Analysis. Clinical Gastroenterology and Hepatology, 2021, 19, 2064-2071.e1.	4.4	8
9	Smoking May Reduce the Effectiveness of Anti-TNF Therapies to Induce Clinical Response and Remission in Crohn's Disease: A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis, 2021, 15, 74-87.	1.3	12
10	Surgery for Inflammatory Bowel Disease Has Unclear Impact on Female Fertility: A Cochrane Collaboration Systematic Review. Journal of the Canadian Association of Gastroenterology, 2021, 4, 115-124.	0.3	6
11	Crohn's and Colitis Canada's 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy. Journal of the Canadian Association of Gastroenterology, 2021, 4, S10-S19.	0.3	2
12	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S1-S9.	0.3	5
13	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S27-S33.	0.3	3
14	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines—Biology, Current Evidence and Recommendations. Journal of the Canadian Association of Gastroenterology, 2021, 4, S54-S60.	0.3	9
15	Suboptimal Vaccination Administration in Mothers With Inflammatory Bowel Disease and Their Biologic-Exposed Infants. Inflammatory Bowel Diseases, 2021, , .	1.9	8
16	The use and impact of monoclonal antibody biologics during pregnancy. Cmaj, 2021, 193, E1129-E1136.	2.0	20
17	Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 1: Live Vaccines. Journal of the Canadian Association of Gastroenterology, 2021, 4, e59-e71.	0.3	6
18	Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 2: Inactivated Vaccines. Journal of the Canadian Association of Gastroenterology, 2021, 4, e72-e91.	0.3	8

#	Article	IF	CITATIONS
19	Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)à€"Part 2: Inactivated Vaccines. Gastroenterology, 2021, 161, 681-700.	1.3	14
20	Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 1: Live Vaccines. Gastroenterology, 2021, 161, 669-680.e0.	1.3	11
21	An Unusual Case of Dysphagia. ACG Case Reports Journal, 2021, 8, e00661.	0.4	0
22	Keep calm and carry on—managing non‶NF antagonist biologics in pregnancy. Alimentary Pharmacology and Therapeutics, 2021, 53, 450-451.	3.7	1
23	Letter: is the radiation therapy causing an IBD flare, or the IBD predisposing to radiation toxicity?. Alimentary Pharmacology and Therapeutics, 2021, 53, 855-856.	3.7	1
24	Management of Inflammatory Bowel Diseases in Special Populations: Obese, Old, or Obstetric. Clinical Gastroenterology and Hepatology, 2020, 18, 1367-1380.	4.4	32
25	Pregnant women with IBD are more likely to be adherent to biologic therapies than other medications. Alimentary Pharmacology and Therapeutics, 2020, 51, 544-552.	3.7	18
26	Localized Gastrointestinal Amyloidosis, Manifesting as an Isolated Colonic Ulcer, is a Rare Cause of Hematochezia. Clinical Gastroenterology and Hepatology, 2020, 18, A25.	4.4	3
27	The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta. Journal of the Canadian Association of Gastroenterology, 2020, 3, 234-242.	0.3	14
28	P511 Association of ustekinumab serum concentrations and clinical outcomes: results from the mUST-DECIDE trial. Journal of Crohn's and Colitis, 2020, 14, S443-S444.	1.3	0
29	Complementary and alternative medications in the management of inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482092755.	3.2	15
30	The impact of pregnancy on biologic therapies for the treatment of inflammatory bowel disease. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2020, 44-45, 101670.	2.4	3
31	Elevated interferon-gamma levels during pregnancy are associated with adverse maternofetal outcomes in IBD. Gut, 2020, 69, 1895-1897.	12.1	0
32	Towards Routine Non-invasive Monitoring of Disease Activity Using Gastrointestinal Ultrasound and Faecal Calprotectin in Pregnant Women With IBD. Journal of Crohn's and Colitis, 2020, 14, 1790-1791.	1.3	2
33	Providing Hospitalized Ulcerative Colitis Patients With Practice Guidelines Improves Patient-Reported Outcomes. Journal of the Canadian Association of Gastroenterology, 2020, 4, 131-136.	0.3	4
34	Knowledge and Attitudes Towards Pregnancy in Females with Inflammatory Bowel Disease: An International, Multi-centre Study. Journal of Crohn's and Colitis, 2020, 14, 1248-1255.	1.3	27
35	Reply. Clinical Gastroenterology and Hepatology, 2020, 18, 1649-1650.	4.4	0
36	Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment. PLoS ONE, 2020, 15, e0227635.	2.5	20

#	Article	IF	CITATIONS
37	Letter: pregnant women with IBD are more likely to be adherent to biologic therapies than other medications—authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 916-917.	3.7	0
38	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. Inflammatory Bowel Diseases, 2019, 25, 1-13.	1.9	73
39	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 1680-1713.	4.4	32
40	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. Journal of the Canadian Association of Gastroenterology, 2019, 2, e1-e34.	0.3	32
41	Editorial: understanding sex and gender dimorphism in chronic diseases may improve outcomes. Alimentary Pharmacology and Therapeutics, 2019, 50, 603-604.	3.7	2
42	The Role of Bowel Ultrasound in Detecting Subclinical Inflammation in Pregnant Women with Crohn's Disease. Journal of the Canadian Association of Gastroenterology, 2019, 2, 153-160.	0.3	15
43	Insights into the role of cannabis in the management of inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481987097.	3.2	25
44	Reduction in surgical stoma rates in Crohn's disease: a populationâ€based time trend analysis. Colorectal Disease, 2019, 21, 1279-1287.	1.4	12
45	A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy. Drugs, 2019, 79, 1053-1063.	10.9	22
46	Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development. The Lancet Gastroenterology and Hepatology, 2019, 4, 287-295.	8.1	44
47	The impact of surgical therapies for inflammatory bowel disease on female fertility. The Cochrane Library, 2019, 7, CD012711.	2.8	22
48	Inflammatory bowel disease and new-onset psychiatric disorders in pregnancy and post partum: a population-based cohort study. Gut, 2019, 68, 1597-1605.	12.1	29
49	Appropriateness of Biologics in the Management of Crohn's Disease Using RAND/UCLA Appropriateness Methodology. Inflammatory Bowel Diseases, 2019, 25, 328-335.	1.9	7
50	Pregnant Women with Inflammatory Bowel Disease Are at Increased Risk of Vitamin D Insufficiency: A Cross-Sectional Study. Journal of Crohn's and Colitis, 2018, 12, 702-709.	1.3	14
51	A Randomized Trial Comparing High Definition Colonoscopy Alone With High Definition Dye Spraying and Electronic Virtual Chromoendoscopy for Detection of Colonic Neoplastic Lesions During IBD Surveillance Colonoscopy. American Journal of Gastroenterology, 2018, 113, 225-234.	0.4	106
52	Not Too Late to Make Cutting-Edge Decisions: Editorial Response to â€ <sup>~</sup> Predictors of Cesarean Delivery in Pregnant Women with Inflammatory Bowel Disease'. Journal of the Canadian Association of Gastroenterology, 2018, 1, 53-53.	0.3	1
53	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. Journal of the Canadian Association of Gastroenterology, 2018, 1, 141-154.	0.3	10
54	Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study. Journal of the Canadian Association of Gastroenterology, 2018, 1, 115-123.	0.3	34

#	Article	IF	CITATIONS
55	Budesonide for the Induction and Maintenance of Remission in Crohn's Disease: Systematic Review and Meta-Analysis for the Cochrane Collaboration. Journal of the Canadian Association of Gastroenterology, 2018, 1, 159-173.	0.3	20
56	Biomarkers in the Management of Crohn's Disease. Gastroenterology, 2018, 154, 2270-2272.	1.3	0
57	Realâ€world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2018, 48, 626-637.	3.7	43
58	Customized Use of Anti-Tumour Necrosis Factor-α Therapy During Pregnancy. Journal of Crohn's and Colitis, 2018, 12, 1379-1380.	1.3	0
59	Clinical, endoscopic and radiographic outcomes with ustekinumab in medicallyâ€refractory Crohn's disease: real world experience from a multicentre cohort. Alimentary Pharmacology and Therapeutics, 2017, 45, 1232-1243.	3.7	141
60	Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease. Inflammatory Bowel Diseases, 2017, 23, 461-472.	1.9	52
61	Editorial: vedolizumab in pregnancy – is gut selectivity as good for baby as it is for mum?. Alimentary Pharmacology and Therapeutics, 2017, 45, 1283-1284.	3.7	8
62	Inflammatory bowel disease in pregnancy. Cmaj, 2017, 189, E669-E669.	2.0	0
63	Biological interventions for maintenance of mucosal healing in Crohn's disease. The Cochrane Library, 2017, , .	2.8	0
64	Editorial: is it time for therapeutic drug monitoring of antiâ€ <scp>TNF</scp> agents during pregnancy? Maybe, maybe not. Author's reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 1556-1557.	3.7	0
65	Asthma Is Associated With Subsequent Development ofÂInflammatory Bowel Disease: A Population-based Case–Control Study. Clinical Gastroenterology and Hepatology, 2017, 15, 1405-1412.e3.	4.4	34
66	The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 1329-1338.	3.7	71
67	Review article: consensus statements on therapeutic drug monitoring of antiâ€ŧumour necrosis factor therapy in inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2017, 46, 1037-1053.	3.7	225
68	Editorial: different tests for different drugs in Crohn's disease, or different tests for different people?. Alimentary Pharmacology and Therapeutics, 2017, 46, 463-464.	3.7	1
69	The NOD2 -Smoking Interaction in Crohn's Disease is likely Specific to the 1007 fs Mutation and may be Explained by Age at Diagnosis: A Meta-Analysis and Case-Only Study. EBioMedicine, 2017, 21, 188-196.	6.1	20
70	Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease. Inflammatory Bowel Diseases, 2017, 23, E26-E37.	1.9	11
71	Surgical Rates for Crohn's Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study. American Journal of Gastroenterology, 2017, 112, 1840-1848.	0.4	140
72	Management of Inflammatory Bowel Disease in Pregnancy: A Practical Approach to New Guidelines. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-4.	1.9	5

#	Article	IF	CITATIONS
73	Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy. Inflammatory Bowel Diseases, 2016, 22, 638-647.	1.9	80
74	Smoking influences the need for surgery in patients with the inflammatory bowel diseases: a systematic review and meta-analysis incorporating disease duration. BMC Gastroenterology, 2016, 16, 143.	2.0	45
75	"Just in Time― When Is It SafeÂto Administer Live Vaccines to Infants Exposed toÂAnti-Tumor Necrosis Factor Agents In Utero?. Gastroenterology, 2016, 151, 1249-1250.	1.3	11
76	513 Pregnancy Alters the Pharmacokinetics of Infliximab and Adalimumab in IBD Women. Gastroenterology, 2016, 150, S105.	1.3	6
77	Targeted Biopsies Identify Larger Proportions of Patients With Colonic Neoplasia Undergoing High-Definition Colonoscopy, Dye Chromoendoscopy, or Electronic Virtual Chromoendoscopy. Clinical Gastroenterology and Hepatology, 2016, 14, 704-712.e4.	4.4	65
78	The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology, 2016, 150, 734-757.e1.	1.3	373
79	Budesonide for induction of remission in Crohn's disease. The Cochrane Library, 2015, 2015, CD000296.	2.8	98
80	Postoperative Mortality Among Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis of Population-Based Studies. Gastroenterology, 2015, 149, 928-937.	1.3	97
81	Intrapartum Corticosteroid use Significantly Increases the Risk of Gestational Diabetes in Women with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2015, 9, 223-230.	1.3	41
82	Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis. Gastroenterology, 2015, 148, 344-354.e5.	1.3	226
83	Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus. Gastroenterology, 2015, 148, 1035-1058.e3.	1.3	323
84	Funding a Smoking Cessation Program for Crohn's Disease: An Economic Evaluation. American Journal of Gastroenterology, 2015, 110, 368-377.	0.4	25
85	Cumulative Incidence of Second Intestinal Resection in Crohn's Disease: A Systematic Review and Meta-Analysis of Population-Based Studies. American Journal of Gastroenterology, 2014, 109, 1739-1748.	0.4	178
86	Budesonide for maintenance of remission in Crohn's disease. The Cochrane Library, 2014, , CD002913.	2.8	61
87	Phenotypic Features of Crohn's Disease Associated With Failure of Medical Treatment. Clinical Gastroenterology and Hepatology, 2014, 12, 434-442.e1.	4.4	56
88	Decreasing Colectomy Rates for Ulcerative Colitis: A Population-Based Time Trend Study. American Journal of Gastroenterology, 2012, 107, 1879-1887.	0.4	174
89	Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut, 2010, 59, 49-54.	12.1	484
90	Novel Anti-Glycan Antibodies Related to Inflammatory Bowel Disease Diagnosis and Phenotype. American Journal of Gastroenterology, 2009, 104, 1426-1434.	0.4	86

#	Article	IF	CITATIONS
91	Managing the risks of IBD therapy. Current Gastroenterology Reports, 2009, 11, 509-517.	2.5	6
92	Budesonide for maintenance of remission in Crohn's disease. , 2009, , CD002913.		43
93	Budesonide for induction of remission in Crohn's disease. , 2008, , CD000296.		70
94	Interventions for maintenance of mucosal healing in ulcerative colitis. The Cochrane Library, 0, , .	2.8	0
95	Biological interventions for induction of mucosal healing in Crohn's disease. The Cochrane Library, 0, , .	2.8	Ο
96	Interventions for induction of mucosal healing in ulcerative colitis. The Cochrane Library, 0, , .	2.8	0
97	Biological interventions for induction of mucosal healing in Crohn's disease. The Cochrane Library, 0, , .	2.8	Ο
98	Interventions for induction and maintenance of mucosal healing in Crohn's disease. The Cochrane Library, 0, , .	2.8	0